Actually, by targeting hypoxia-inducible factor 1-alpha (HIF-1α) via cytoplasmic sequestration and subsequent up-regulation of the von Hippel–Lindau tumor suppressor (VHL), EF24 addresses HCC resistance and establishes a breakthrough approach [38]. Here, VHL is linked to hepatocellular carcinoma.